Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
CNY 23.6
(-0.3%)
CNY 23.6
(-0.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 418.43 Million CNY | 78.31% |
| 2022 | 234.67 Million CNY | -2.52% |
| 2021 | 240.74 Million CNY | -65.69% |
| 2020 | 701.72 Million CNY | 57.39% |
| 2019 | 445.84 Million CNY | 1.45% |
| 2018 | 439.47 Million CNY | 37.8% |
| 2017 | 318.92 Million CNY | 116.41% |
| 2016 | 147.36 Million CNY | -9.33% |
| 2015 | 162.53 Million CNY | -8.18% |
| 2014 | 177.02 Million CNY | -12.23% |
| 2013 | 201.67 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 478.64 Million CNY | 5.09% |
| 2024 Q1 | 438.59 Million CNY | 4.82% |
| 2024 Q2 | 455.45 Million CNY | 3.85% |
| 2023 Q2 | 359.16 Million CNY | 21.1% |
| 2023 FY | 418.43 Million CNY | 78.31% |
| 2023 Q3 | 363.47 Million CNY | 1.2% |
| 2023 Q4 | 418.43 Million CNY | 15.12% |
| 2023 Q1 | 296.58 Million CNY | 26.38% |
| 2022 Q3 | 204.3 Million CNY | 3.56% |
| 2022 Q1 | 198.42 Million CNY | -17.58% |
| 2022 FY | 234.67 Million CNY | -2.52% |
| 2022 Q4 | 234.67 Million CNY | 14.86% |
| 2022 Q2 | 197.28 Million CNY | -0.58% |
| 2021 Q2 | 624 Million CNY | 2.02% |
| 2021 FY | 240.74 Million CNY | -65.69% |
| 2021 Q4 | 240.74 Million CNY | 15.6% |
| 2021 Q3 | 208.25 Million CNY | -66.63% |
| 2021 Q1 | 611.65 Million CNY | -12.84% |
| 2020 Q3 | 811.01 Million CNY | 99.37% |
| 2020 Q4 | 701.72 Million CNY | -13.48% |
| 2020 FY | 701.72 Million CNY | 57.39% |
| 2020 Q2 | 406.77 Million CNY | 18.97% |
| 2020 Q1 | 341.91 Million CNY | -23.31% |
| 2019 FY | 445.84 Million CNY | 1.45% |
| 2019 Q4 | 445.84 Million CNY | 4.22% |
| 2019 Q3 | 427.77 Million CNY | -10.61% |
| 2019 Q1 | 419.59 Million CNY | -4.52% |
| 2019 Q2 | 478.54 Million CNY | 14.05% |
| 2018 Q4 | 439.47 Million CNY | 9.98% |
| 2018 FY | 439.47 Million CNY | 37.8% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 Q2 | 407.14 Million CNY | 0.0% |
| 2018 Q3 | 399.59 Million CNY | -1.85% |
| 2017 Q4 | 318.92 Million CNY | 0.0% |
| 2017 FY | 318.92 Million CNY | 116.41% |
| 2016 Q4 | 147.36 Million CNY | 0.0% |
| 2016 FY | 147.36 Million CNY | -9.33% |
| 2016 Q2 | 143.94 Million CNY | 0.0% |
| 2015 FY | 162.53 Million CNY | -8.18% |
| 2014 FY | 177.02 Million CNY | -12.23% |
| 2013 FY | 201.67 Million CNY | 0.0% |